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ABSTRACT
Objective: The objective of this study was to provide a
detailed comparative microcosting analysis for two cancer
treatment pathways to contribute evidence for resource allo-
cation and operational decision-making in a Canadian cancer
care context.
Methods: We estimated direct medical costs (in 2004 CAN$)
of the entire pathway of care for diffuse large B-cell lym-
phoma (DLBCL) patients in a large Canadian cancer treat-
ment center. Patient samples were deﬁned as those who
received R-CHOP (rituximab plus cyclophosphamide, doxo-
rubicin, vincristine, and prednisone; n = 85) or CHOP (i.e.,
without rituximab; n = 86) as ﬁrst-line treatment. All subse-
quent treatments including palliative care for these patient
samples were assessed. Hospitalization costs and unit costs of
medical resources were collected from integrated medical
organizations. Individual patient resource consumption was
assessed via medical chart review.
Results: For ﬁrst-line treatment, drug cost was the largest
contributor to total cost, followed by hospitalization cost.
Rituximab was the largest contributor to mean cost differ-
ences between R-CHOP and CHOP treatments. For treat-
ments subsequent to ﬁrst-line treatment, no signiﬁcant cost
differences were found. Hospitalization and transplantation
costs were the two largest constituents of total costs subse-
quent to ﬁrst-line treatment, followed by drug cost. Patients
with advanced stage disease cost signiﬁcantly more than
patients with limited stage disease.
Conclusion: This is the ﬁrst detailed microcosting study that
has employed consistent local data to estimate total medical
costs for DLBCL patients in Canada. This information is
useful for resource allocation planning and operational deci-
sions, because it provides more substantive, relevant evidence
as compared to aggregated, literature or extrapolated
information.
Keywords: chemotherapy, CHOP, drug combinations,
economics, health-care costs, microcosting, neoplasms,
R-CHOP.
Introduction
Diffuse large B-cell lymphoma (DLBCL) is the most
common lymphoma subtype, representing approxi-
mately 30% of all lymphoma cases [1,2]. Until
recently, CHOP (cyclophosphamide, doxorubicin, vin-
cristine, and prednisone) was the most widely used
chemotherapy for DLBCL [3]. Because several ran-
domized clinical trials reported signiﬁcantly improved
treatment outcomes associated with the addition of
rituximab (a chimeric monoclonal antibody against
the CD20 B-cell antigen) to CHOP [4–8], R-CHOP is
now being widely accepted as the standard ﬁrst-line
treatment (i.e., the initial treatment of choice) in clini-
cal practice, despite its higher cost.
Cost-effectiveness analyses (which have included
detailed cost analyses) for CHOP and R-CHOP as
ﬁrst-line DLBCL treatment have been conducted
[9–15]. Van Agthoven et al. [16] review these studies in
detail. The general conclusion from these studies was
that R-CHOP is a more desirable treatment from an
effectiveness and cost-effectiveness perspective com-
pared to CHOP. Nevertheless, some of these studies
[9–12] used approximations relying on secondary data
sources for many costs, or were based on other health-
care systems [13–15] thus the relevance to publicly
funded, integrated systems such as Canada’s is limited.
The overall objective of this study was to provide
a detailed comparative microcosting analysis for
R-CHOP and CHOP treatment pathways (including
treatments subsequent to ﬁrst-line treatment) to con-
tribute evidence for resource allocation and operational
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decision-making in a Canadian cancer care context. All
data were obtained from local primary sources that
comprise an integrated care setting. Speciﬁc objectives
were to: 1) estimate and compare the direct medical
costs associated with R-CHOP and CHOP as the ﬁrst-
line treatments for DLBCL; 2) analyze costs of subse-
quent treatments; and 3) determine how particular
patient characteristics inﬂuenced costs.
Materials and Methods
We conducted a retrospective analysis primarily based
on local data from the Tom Baker Cancer Center
(TBCC) in Calgary, Alberta (a comprehensive inte-
grated cancer treatment center serving a population of
more than one million people), as well as the Calgary
Health Region (CHR; for hospitalization data) and
Calgary Laboratory Services (CLS; for testing data).
R-CHOP was introduced to the TBCC in 2001, and it
has largely replaced CHOP as the standard ﬁrst-line
treatment for DLBCL patients, especially for elderly
patients (i.e., older than 60 years). Our study quanti-
ﬁed detailed “door-to-door” costs for the patients,
from the time they enter the TBCC cancer care system
to cure, end of treatment, or end of life (including
palliative therapy).
Patients receiving R-CHOP (n = 85) (i.e., the
“R-CHOP sample”) as ﬁrst-line treatment from Febru-
ary 2001 to July 2004 were selected from the TBCC’s
lymphoma database. Most patients were more than
60 years of age. A comparison sample of 86 patients
receiving CHOP as ﬁrst-line treatment (i.e., “the CHOP
sample”) was selected by matching on the baseline
characteristics of the R-CHOP sample (Table 1). In the
TBCC, 216 patients received CHOP as the ﬁrst-line
treatment from January 1998 to July 2004.
Pretreatment diagnostic phases (i.e., before admis-
sion to the TBCC) were not included in our study. In
the two samples, every patient went through R-CHOP
or CHOP administration, and only patients who
relapsed after or who were refractory to the ﬁrst-line
treatment received subsequent treatments (Fig. 1).
Thus, our study divided the entire treatment process
into two parts for cost analysis: 1) ﬁrst-line treatment;
and 2) subsequent treatment. Following local guide-
lines, an expert oncologist’s (coauthor DS) opinion,
and a previous study [13], the ﬁrst-line treatment was
divided into “assessment” (the day of ﬁrst admission
to the TBCC until the day before the start of the ﬁrst
cycle of R-CHOP or CHOP, including clinic visit,
staging tests, and hospitalization), “administration”
(start of the ﬁrst cycle of R-CHOP or CHOP until
3 weeks after the last cycle, including chemotherapy,
adjuvant radiotherapy, restaging tests, and hospitaliza-
tion), and “follow-up” (day after administration until
1 year later, including tests and hospitalization). The
follow-up phase was not evaluated for those patients
who died or voluntarily ceased participation during
and immediately after the chemotherapy administra-
tion. For patients who died or relapsed during follow-
up, the follow-up phase was censored at the death or
recurrent date, which resulted in follow-up lengths less
than 1 year.
Subsequent treatment was divided into “second-line
treatment,” “third-line treatment,” “fourth-line treat-
ment,” and “palliative care.” Each treatment type
included the potential for chemotherapy, radiotherapy,
autologous stem-cell transplantation (ASCT), and
other miscellaneous treatments (Fig. 1). In practice at
the TBCC, palliative care could be used at any time
after the ﬁrst-line treatment. Every patient who
relapses and dies from lymphoma eventually receives
palliative care before death. On average, DLBCL
patients received 45 days of palliative care. Because of
the wide variety of palliative care choices compared to
other treatments, and the unique costing method
(detailed below), palliative care was listed as a separate
phase, in the R-CHOP sample, DLBCL was the only
cause of death. In the CHOP sample, three patients
died of a second cancer, one patient died of stroke, one
patient died of suicide, one patient died of infection,
and two patients died for other nonspeciﬁed reasons.
Micro-costing methods [17,18] were applied to
estimate the costs of most categories (see Table 2
for representative unit costs). Three main medical
organizations (TBCC, CHR, and CLS) were involved
Table 1 Patient characteristics: R-CHOP and CHOP samples
Patient characteristics
R-CHOP
(n = 85)
CHOP
(n = 86)
Age (years)
Mean (SD) 68.7 (12.1) 66.8 (12.2)
Range (%) 21–90 22–86
60 11.8 16.3
>60 88.2 83.7
Sex (%)
Male 64.7 50.0
Female 35.3 50.0
Original stage (%)*
Limited (I or II) 31.8 37.2
Advanced (III or IV) 68.2 62.8
ECOG performance score (%)†
ECOG score 0 or 1 77.6 65.1
ECOG score 2–4 22.4 34.9
*According to guidelines for Hematology Tumor Group members in the Tom Baker
Cancer Center: Limited stage: nonbulky stage IA(E) or IIA(E) (3 adjacent lymph
node regions); advanced stage: stage II involving >3 or nonadjacent lymph node
regions or stage III or IV or B symptoms or bulky tumor mass (10 cm).
†ECOG performance status:
0: Fully active, able to carry on all predisease activities without restriction.
1: Restricted in physically strenuous activity but ambulatory and able to carry out
work of a light or sedentary nature (e.g., light housework, ofﬁce work).
2: Ambulatory and capable of all self-care but unable to carry out any work activities.
Up and about more than 50% of waking hours.
3:Capable of only limited self-care.Conﬁned to bed or chair more than 50% of waking
hours.
4: Completely disabled. Cannot self-care.Totally conﬁned to bed or chair.
This and following P-values relate to percentage comparisons; complementary com-
parisons are not shown.
Note: None of the variables differed signiﬁcantly (at alpha of 0.05).
ECOG, Eastern Cooperative Oncology Group.
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with the entire treatment process. Most tests were
conducted via CLS; except for computed tomography
(CT), positron emission tomography, bone scans, and
magnetic resonance imaging, which were conducted in
the CHR. Patients received treatments in the TBCC
and were hospitalized in CHR facilities if needed. The
TBCC nursing unit provided outpatient-nursing costs,
and drug costs were obtained from the TBCC Phar-
macy Department. Most test costs were estimated
from CLS clinical trial costs, and the remaining, pro-
vided by the CHR. Standard physician-billing rates to
the provincial health department (Alberta Health and
Wellness) were employed for unit oncologist costs.
Additionally, medical chart review was conducted
for all patients to determine precise treatment process
details during a period beginning with ﬁrst admission
and ending with last contact. The medical infor-
mation extracted via chart review included: tests
conducted during the different phases; detailed in-
formation regarding administered chemotherapies,
radiotherapy, and other treatments; and, follow-up
information.
Individual patient costs associated with the entire
process, with the exception of hospitalization and
palliative care costs, were calculated by multiplying
individual medical resource consumption by the corre-
sponding unit costs. Nevertheless, CHR has an inte-
grated database that tracks individual hospitalization
costs. Thus, the Patient Health Number for each
patient in the samples was used to query this database
and to estimate total individual hospitalization costs.
These included costs of clinical laboratories, diagnosis,
Palliative care, death 
R-CHOP n=5 
CHOP n=13
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R-CHOP n=16 
CHOP n=38 
Cure, surveillance, 
or end of treatment 
R-CHOP n=64 
CHOP n=35 
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CHOP n=86
Second-line 
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CHOP n=2 
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“Other” 
Figure 1 Flow chart of treatment for R-CHOP and CHOP patient samples. Notes: Rectangles denote treatment choices, and ovals denote outcomes of
the treatments. Numbers of patients in different categories are total numbers. Note that these numbers may differ from cost tables because of missing
data. In our sample population, no patients survived subsequent to fourth-line treatment. Detailed numbers for speciﬁc treatments are available upon
request.“Cure” indicates 5-year event-free survival.“Surveillance” indicates response, but less than 5-year follow-up.All patients receive(d) palliative care
before death.“ASCT” is autologous stem-cell transplantation. For the R-CHOP sample, second-line chemotherapies potentially included: rituximab, GDP
(gemcitabine, cisplatin, dexamethasone), DICEP (cyclophosphamide, cisplatin, etoposide), POKE (epirubicin, vincristine, cyclophosphamide, prednisone),
methotrexate, gemitabine+cyclophosphamide. “Other” second-line chemotherapies included: cyclophosphamide and decadron. For the CHOP sample,
second-line chemotherapies potentially included: CHOP, DICEP, CEPP (cyclophosphamide, VP16, procarbazine, prednisone), cyclosphosphamide+
VP16+viscristine, ICE (ifosphomide, cisplatin, etoposide), cyclophosphamide+mitoxantrone+carboplatin. Third-line chemotherapies potentially included:
GDP,methotrexate+cytosine+arabinoside+hydrocortisone, cyclophosphamide+vincristine+methylprednisolone, etoposide+prednisone.“Other” third-line
treatment included thiotepa. Fourth-line chemotherapy included GDP.
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cardio diagnostic laboratory, inpatient nursing unit,
operating room, recovery room, bone marrow assess-
ment, respiratory therapy, audiology/speech, clinical
nutrition, occupational therapy, physiotherapy, social
work, day surgery, ambulatory care, surgery supply,
and drugs. ASCT is a particularly expensive treatment
that was included in CHR costs.
Palliative care can be administered in the patient’s
home, nursing home, residential hospice or hospital.
Therefore, a group of 33 DLBCL patients treated in
Calgary from 1997 to 2000 was extracted from a
separate palliative care research database [19]. A
microcosting method was used to determine the indi-
vidual palliative care costs for this group, which
included costs of drugs, physicians, hospitalization,
home care, nursing home care, and residential hospice
care (provided by not-for-proﬁt agencies in Calgary).
The mean individual palliative care cost based on this
group was calculated with a mean referral time of
45 days to death, and it was added to the individual
total treatment cost for each patient who received pal-
liative care in the R-CHOP and CHOP samples.
Only direct medical costs were included in analyses,
and all costs were converted to 2004 Canadian dollars.
All costs reported relate to patients, not admissions.
No discounting was applied, because costs were aggre-
gated over a relatively short period of time. The
Mann–Whitney U-test was used for statistical com-
parisons between two groups, because distributions
were highly skewed [20]. Alpha was set at 0.05, and
95% conﬁdence intervals (95% CIs) for differences
between medians are presented for cost comparisons.
Results
Baseline characteristics of the two samples showed
that 88.2% and 83.7% patients were older than
60 years (mean age 68.7 and 66.8 years), and 68.2%
patients had advanced stage disease (Table 1). Because
of missing data and differential survival, the sample
sizes varied during the different phases.
Representative unit costs are provided in Table 2.
Cost information for ﬁrst-line R-CHOP treatment is
provided in Table 3. The assessment phase lasted a
Table 2 Representative unit costs (2004 CAN$)
Outpatient visits Unit cost Source
Oncologist 141.70 Tom Baker Cancer Center
Nurse 58.00 Tom Baker Cancer Center
Inpatient visits*
Hospital admission—oncologist 112.94 Tom Baker Cancer Center
Hospitalization visit/day—oncologist 36.71 Tom Baker Cancer Center
Laboratory tests
Bone marrow aspiration and biopsy 143.40 Calgary Laboratory Services
Bone marrow biopsy—oncologist 39.95 Tom Baker Cancer Center
Flow cytometry—lymphoma panel 383.69 Calgary Laboratory Services
Cerebrospinal ﬂuid cytology 87.10 Calgary Laboratory Services
HIV serology 10.18 Calgary
Chest x-ray 29.19 Elliot, Fong,Wallace Associates
Bone scan 221.72 Calgary
Magnetic resonance imaging 350.30 Calgary
Positron emission tomography/computed tomography scan 1161.14 Calgary
Computed tomography scan (neck) 194.55 Calgary
Computed tomography (head) 200.00 Calgary
Computed tomography (chest) 289.22 Calgary
Computed tomography (chest and abdomen) 425.63 Calgary
Computed tomography (abdomen and pelvis) 314.10 Calgary
Computed tomography (chest, abdomen, pelvis) 445.00 Calgary
Electrolytes 21.32 Calgary Laboratory Services
Diagnostic procedures
Pathology review 150.00 Tom Baker Cancer Center
Radiation therapy (20 fractions) 1855.50 Tom Baker Cancer Center
Chemotherapy (per cycle)†
Oncologist 56.47 Tom Baker Cancer Center
Nursing—initial visit 84.80 Tom Baker Cancer Center
CHOP—drug 608.00 Tom Baker Cancer Center
CHOP—nursing 105.90 Tom Baker Cancer Center
R-CHOP—drug 3878.00 Tom Baker Cancer Center
R-CHOP—nursing 151.62 Tom Baker Cancer Center
Ifosphomide, cisplatin, etoposide—drug 2482.00 Tom Baker Cancer Center
Gemcitabine, cisplatin, dexamethasone—drug 1146.00 Tom Baker Cancer Center
Gemcitabine, cisplatin, dexamethasone—nursing 149.61 Tom Baker Cancer Center
Cyclophosphamide, cisplatin, etoposide—drug 2028.00 Tom Baker Cancer Center
*Hospitalization and autologous stem-cell transplantation costs were determined on a per-patient basis.
†Only the most common treatments are included; other drug costs available upon request.
Notes: Most unit costs listed include the related costs of technician time, supplies, and overhead if applicable. Unit costs less than $10 CAN (e.g., many blood tests) are not
included; data available upon request.
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mean of 24.1 days. During this process, all patients
went through clinic visits and staging tests, and 47.6%
patients were hospitalized. On average, patients cost
$4359 during this phase, with 67.8% ($2954) of the
total cost attributable to hospitalization (mean dura-
tion of 3.3 days and frequency of 47.6%). The second
highest cost component in this phase was test cost,
which was more than twice of the sum of oncologist
and outpatient nursing costs. CT, ﬂow cytometry, and
bone marrow biopsy were the top three most costly
tests.
R-CHOP patients cost an average of $33,087
during the administration phase (with mean duration
of 140.9 days). In this phase, all patients received che-
motherapy and restaging tests, and four patients died.
On average, 5.9 cycles of chemotherapy were admin-
istered and 31% patients received radiotherapy. Drug
cost was the highest cost (70% of total). Hospitaliza-
tion cost was the second most important cost (22.1%
of total) with 42.9% frequency and average duration
of 6.7 days. Oncologist cost was similar to outpatient
nursing cost, both of which were increased compared
with the assessment phase because of more extensive
involvement, especially for outpatient nursing cost.
Because of the smaller numbers of tests administered
during this phase, test cost was less than half compared
to the assessment phase.
The mean total cost of the follow-up phase was
$3215. Hospitalization cost accounted for 72.5% of
the total cost, and was the largest cost component.
Nevertheless, hospitalization frequency during this
phase was only 12.5%, which means the average hos-
pitalization cost was driven by only a small number of
patients. The mean duration of hospitalization was
2.3 days. There was no outpatient nursing cost and
only minor oncologist cost. Test cost increased during
this phase compared with the treatment phase, mainly
because of the higher cost of CT.
Costs between the R-CHOP and CHOP samples
were compared to determine the cost difference and
whether this difference was solely attributable to the
additional drug cost of rituximab (Table 3). In general,
the costs of the R-CHOP sample were not signiﬁcantly
different from those of the CHOP sample during the
assessment and follow-up phases. For patients who
completed the three phases in the two samples, the
difference between their total costs was only attribut-
able to the additional cost of adding rituximab to
CHOP. Thus, the cost of rituximab was the only sig-
niﬁcant factor driving the total medical cost of the
R-CHOP sample higher compared to the CHOP
sample. Comparison of patient variables between the
two samples further veriﬁed the above conclusion
(Table 4). Except for the hospitalization length during
the follow-up phase, none of the patient variables dif-
fered signiﬁcantly. CHOP patients on average cost
nearly three times as much as R-CHOP patients during
the follow-up phase, although the difference was not
Table 3 Costs per patient associated with R-CHOP and CHOP samples: ﬁrst-line treatment (2004 CAN$)
Mean SD Med. Max. Min. Mean SD Med. Max. Min.
R-CHOP (n = 84)¶ CHOP (n = 81)¶
Assessment
Oncologists* 351 253 181 1,762 141 326 193 181 808 141
Outpatient nursing† 58 0 58 58 58 58 0 58 58 0
Staging tests‡ 996 407 1,062 2,181 71 932 415 1,003 2,114 71
Hospitalization 2,954 5,385 0 40,207 0 2,458 3,255 0 14,196 0
Total§ 4,359 5,621 1,737 43,365 270 3,773 3,437 1,976 15,605 270
R-CHOP (n = 84)¶ CHOP (n = 78)¶
Treatment
Drugs 23,164 6,027 23,681 31,575 11,841 3,408 1,306 3,997 5,329 666
Oncologists 625 598 404 4,089 169 552 351 367 1,807 56
Outpatient nursing 975 232 995 1,298 540 627 208 720 932 191
Radiotherapy 580 889 0 3,329 0 455 931 0 3,711 0
Tests 431 344 475 1,569 26 363 432 250 2,147 9
Hospitalization 7,311 14,069 0 65,041 0 6,836 15,785 0 116,123 0
Total 33,088 15,978 28,247 94,734 13,979 12,240 16,107 6,504 126,415 2,704
R-CHOP (n = 72)¶ CHOP (n = 67)¶
Follow-up
Oncologists 100 363 0 2,213 0 259 645 0 3,671 0
Tests 785 740 714 3,642 0 753 961 445 5,783 0
Hospitalization 2,330 7,919 0 47,615 0 7,917 22,743 0 138,145 0
Total 3,215 8,303 890 50,179 0 8,929 23,961 709 147,600 0
*Includes consult, bone marrow biopsy, hospital admission, and visits.
†Standard minimal charge.
‡Includes pathology review, bone marrow assessment, computed tomography, bone scan, ﬂow cytometry, magnetic resonance imaging, beta-2-microglobulin, complete history and
physical examination with Eastern Cooperative Oncology Group Performance Score, complete blood count and differential, serum creatinine, electrolytes, alkaline phosphatase,
alanine transaminase, lactate dehydrogenase, bilirubin, total protein, albumin, calcium, erythrocyte sedimentation rate (for early stage Hodgkin’s lymphoma).
§Note that “total” statistics are relevant to individual patients, e.g., the maximum total assessment cost for the R-CHOP sample ($43,365) reﬂects the patient with the maximum
cost, not the sum of maximums.
¶Numbers of patients were reduced compared to Table 1, because of death or missing data.
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signiﬁcant. This was mainly caused by the higher hos-
pitalization cost of CHOP patients during this phase.
Most patients who were refractory or relapsed after
the ﬁrst-line treatment were subject to extensive
subsequent treatments (including ASCT), ultimately
resulting in palliative care if the cancer was not cured
(Fig. 1). There were signiﬁcantly more patients who
died or were refractory/relapsed after CHOP treatment
as compared to patients who died or were refractory/
relapsed after R-CHOP (24.7% vs. 59.3%, P =
0.0003). All patients who were refractory/relapsed
after R-CHOP received second-line treatment (except
one patient who died immediately). Thirty-two of the
38 patients refractory/relapsed after CHOP received
second-line treatment. Of the remaining, four received
palliative care directly, one died immediately, and one
exited the process voluntarily.
Signiﬁcantly more CHOP patients died or were
refractory/relapsed after the second and third-line
treatments, respectively, compared to R-CHOP
patients (37.2% vs. 12.9%, P = 0.0002; 11.6% vs.
1.2%, P = 0.005). The percentages of patients who
were administered ASCT in the two samples were
insigniﬁcantly different (3.5% vs. 8.1%). During the
entire treatment process, 16 R-CHOP patients died
because of DLBCL. In the CHOP sample, 49 patients
died, 41 of whom were attributed to DLBCL. Thus, 16
R-CHOP patients (18.6%) and 41 CHOP patients
(47.7%) received palliative care before death.
Table 5 provides cost comparisons between the two
samples during all treatments subsequent to the ﬁrst-
line treatment. Because of missing hospitalization costs
for some patients, the patient numbers used to calcu-
late the costs were less than the actual numbers of
patients who consumed the medical care. For both
samples during the second-line treatment, hospitaliza-
tion and transplantation costs were the two largest
components, and drug cost was the third largest.
The mean costs of the CHOP sample during the
third- and fourth-line treatments were appreciably
larger than those of the R-CHOP sample (except for
radiotherapy cost during the third-line treatment),
because only one R-CHOP patient received radio-
therapy as the third-line treatment and none went
through a fourth-line treatment. Palliative care costs
were assumed to be the same for the two samples.
The total costs of all phases subsequent to ﬁrst-line
treatment were all positively skewed, suggesting that
only a minority of patients consumed the majority of
resources. ASCT is a particularly high-cost treatment.
From the CHR database, the average unit cost of
ASCT was $48,402 including inpatient and outpatient
costs. We conducted further cost analysis on the
patients who were administered by ASCT in the two
samples. We found that the highest individual total
costs subsequent to ﬁrst-line treatment in the two
samples were all associated with patients who had
ASCT.
Total costs during the entire treatment process
(including ﬁrst-line treatment and subsequent treat-
ment) are provided in Table 6. These estimates are
based on 71 patients in the R-CHOP sample and 60
patients in the CHOP sample (difference because of
missing data and differential survival). There was no
relationship between the patients with highest costs
during the ﬁrst-line treatment and patients with
highest costs during the subsequent phases. Patients
who received ASCT still cost the most when individual
total costs during the whole process were considered.
This ﬁnding indicates that transplantation is the most
important contributor to the entire treatment cost.
Patient age, stage, tumor bulk, and comorbid illness
are generally considered when treatment plans for
individual patients are prescribed, which in turn may
affect treatment costs. We analyzed “age” and “stage”
inﬂuences on costs in the R-CHOP sample only,
Table 4 Treatment variables: R-CHOP and CHOP samples
Mean SD Med. Max. Min. Mean SD Med. Max. Min.
R-CHOP (n = 84) CHOP (n = 81)
Assessment
Duration of phase (days) 24.2 23.5 17.0 131.0 0.0* 19.0 21.0 14.0 144.0 0.0*
Hospitalization frequency (%) 47.6 — — — — 48.8 50.3 — — —
Hospitalization length (days) 3.3 5.8 0.0 40.0 0.0 2.8 4.0 0.0 15.0 0.0
R-CHOP (n = 84) CHOP (n = 78)
Treatment
Duration of phase (days) 141.0 34.1 147.0 189.0 63.0 125.7 44.9 147.0 189.0 22.0
Treatment cycles (n) 5.9 1.5 6.0 8.0 3.0 5.1 2.0 6.0 8.0 1.0
Hospitalization frequency (%) 42.9 — — — — 43.6 — — — —
Hospitalization length (days) 6.7 14.6 0.0 96.0 0.0 5.8 8.9 0.0 40.0 0.0
R-CHOP (n = 72) CHOP (n = 67)
Follow-up
Duration of phase (days) 286.7 121.9 365.0 365.0 4.0 279.8 128.8 365.0 365.0 5.0
Hospitalization frequency (%) 12.5 — — — — 20.9 — — — —
Hospitalization length (days) 2.3 8.2 0.0 48.0 0.0 6.4 16.6 0.0 100.0 0.0
*As the records indicated, a small number of patients started the ﬁrst cycle of the chemotherapy at the day of ﬁrst admission to the TBCC.
Note: None of the variables differed signiﬁcantly (at alpha of 0.05), other than hospitalization length during the follow-up phase.
TBCC,Tom Baker Cancer Center.
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because this information was relatively complete and
readily available in the databases. For subsequent
treatment, only effects on patient distributions of
receiving medical care were analyzed, because further
statistical analysis on costs was not possible because of
small patient numbers.
R-CHOP patients were divided into “younger”
(60) and “elderly” (>60). For ﬁrst-line treatment,
younger patients cost more than elderly patients
during the administration and follow-up phases, but
the cost differences were largely insigniﬁcant. Younger
patients only cost signiﬁcantly more than elderly
patients in the “other costs” category (Table 7) during
the administration phase (P = 0.0006; 95% CI 807–
2254). No signiﬁcant differences between the numbers
of younger and elderly patients who died or were
refractory/relapsed after each line treatment and thus
received further medical care were found.
“Limited stage” and “advanced stage” groups were
deﬁned based on the staging information of individual
patients in the database. Costs for limited stage
patients were lower than those for patients at
advanced stage during the ﬁrst-line treatment
(Table 7), and signiﬁcant differences between the
limited and advanced patient groups were associated
with drug cost (P < 0.0001; 95% CI -11,841 to 0),
hospitalization cost (P = 0.02; 95% CI -5024 to 0)
and total cost during the administration phase
(P = 0.0003; 95% CI -14,596 to -4718).
Advanced stage patients had a signiﬁcantly longer
duration of the administration phase (P = 0.0007),
more cycles of R-CHOP (P = 0.0003), higher hospital-
ization frequency (P = 0.02) and longer hospitalization
length (P = 0.03) during the administration phase. An
exception was that limited stage patients had longer
duration of assessment (P = 0.009) than advanced
stage patients (Table 8). After the ﬁrst-line treatment,
signiﬁcantly more patients at advanced stage died or
Table 5 Costs per patient associated with R-CHOP and CHOP samples: subsequent (after ﬁrst-line) treatments (2004 CAN$)
Mean SD Med. Max. Min. Mean SD Med. Max. Min.
R-CHOP (n = 13)¶ CHOP (n = 28)¶
Second-line treatment
Drugs 2,217 3,499 1,910 13,183 0 5,379 6,935 2,159 2,3681 0
Oncologists 982 917 757 2,462 0 811 886 456 3,479 0
Outpatient nursing 568 786 280 1,931 0 627 770 238 2,211 0
Tests 1,872 1,708 1,207 6,233 0 1,159 1,186 925 5,998 0
Radiotherapy 1,063 881 1,601 1,856 0 891 911 800 1,856 0
Hospitalization* 13,013 14,607 8,407 42,714 0 10,060 15,778 1,452 66,496 0
ASCT† 13,782 30,115 0 101,754 0 6,552 13,043 0 38,129 0
Total‡ 33,498 33,802 16,072 110,471 2,246 25,479 25,739 15,867 102,999 1,856
R-CHOP (n = 1)¶ CHOP (n = 11)¶
Third-line treatment
Drugs 0 463 712 220 2,410 0
Oncologists 874 1,058 282 2,948 0
Outpatient Nursing 700 1,423 280 4,897 0
Radiotherapy 1,856 0 1,856 1,856 1,856 1,643 1,478 1,601 4,859 0
Tests 0 839 836 459 2,693 0
Hospitalization 10,885 18,976 2,731 60,334 0
Total 1,856 0 1,856 1,856 1,856 15,393 19,231 6,866 65,357 1,856
R-CHOP (n = 0)¶ CHOP (n = 3)¶
Fourth-line treatment
Drugs Not applicable 2,390 2,390 2,390 4,780 0
Oncologists 151 130 226 226 0
Outpatient nursing 373 323 560 560 0
Radiotherapy 1,426 2,470 0 4,279 0
Tests 297 514 0 890 0
Total 4,637 1,669 4,279 6,456 3,176
R-CHOP (n = 16) CHOP (n = 41)
Palliative care§ 3,671 3,510 2,782 16,966 37 3,671 3,510 2,782 16,966 37
*Hospitalization cost includes all costs occurring during hospitalization except for transplantation, which is listed as a separate item.
†ASCT cost only included inpatient costs; outpatient costs during this process were included in other categories (i.e., drugs, oncologists, outpatient nursing, and tests).
‡Note that “total” statistics are relevant to individual patients.
§Includes physician, nursing, hospitalization, drug, hospice, etc. costs; for details please see referenced study in text. Costs are assumed to be equal across R-CHOP and CHOP
samples, because speciﬁc information for these samples was not available.
¶Numbers of patients were reduced compared to previous tables and Figure 1 because of death or missing data.
ASCT, autologous stem-cell transplantation.
Table 6 Total costs for R-CHOP and CHOP samples (2004
CAN$)
R-CHOP (n = 71) CHOP (n = 60)
Mean (SD) 47,377 (31,987) 35,292 (41,675)
Median 37,693 18,156
Range: minimum, maximum 15,489,170,141 6,156, 207,831
Mean cost for 90th percentile (SD) 12,7852 (30,129) 135,110 (52,724)
Mean cost for 10th percentile (SD) 17,390 (1,125) 6,866 (532)
Note: 71 R-CHOP patients and 60 CHOP patients were used to calculate these
values, because these were the numbers of patients in the respective samples for
which complete data were available throughout the process.
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were refractory/relapsed than patients at limited stage
(P = 0.003). Therefore, stage was likely to be a more
signiﬁcant inﬂuence on cost than age in these patients.
Discussion
To our knowledge, this is the ﬁrst detailed microcost-
ing study using local primary data on the entire
pathway of care for DLBCL patients treated with
R-CHOP and CHOP as ﬁrst-line treatments in a Cana-
dian context. Although other studies (summarized in
van Agthoven et al. [16]) have performed microcosting
for these types of patients, it is difﬁcult to interpret the
results of these studies as compared to the current one,
because: 1) they have not been conducted in a Cana-
dian health-care system; 2) they have used multiple
sources of aggregated, extrapolated, and/or literature-
based data (as opposed to local, consistent data from
integrated care that were veriﬁed using patient charts);
and/or 3) they have not necessarily evaluated the entire
pathway of care. For the purpose of decision-making
in integrated Canadian or other publicly funded cancer
care organizations, we feel that our methods and
results will be more relevant than these other studies.
Nevertheless, there are several limitations to our
study. It was not meaningful to estimate overall or
event-free survival in our study samples, because the
R-CHOP sample was not followed as long as the
CHOP sample. A prospective study would elucidate
relative survival and thus provide a useful clinical
outcome for subsequent analysis. Nevertheless,
quality-of-life would be a better comparative measure,
because this incorporates morbidity (e.g., adverse
events) as well as mortality. Moreover, CHOP has
largely been replaced by R-CHOP as a standard treat-
ment for DLBCL. Regardless, we feel the cost com-
parisons are informative, because they demonstrate the
value of detailed cost comparisons in a constantly
changing landscape of drugs and treatments.
There were some data that were missing because of
a lack of recorded costs. The speciﬁc reasons for this
could not be determined retrospectively. We did not
incorporate patients with missing data into our cost
estimates, because this would have introduced a down-
ward bias. Although difﬁcult to determine precisely, it
is unlikely that excluding these patients from our
analysis would introduce bias, because there is no
reason to expect that there would be a systematic
Table 7 Costs per patient for R-CHOP sample (2004 CAN$): age and stage group comparisons
Mean SD Med. Max. Min. Mean SD Med. Max. Min.
Age
60 (n = 10) >60 (n = 74)
Assessment
Hospitalization 2,449 2,981 1,022 8,164 0 3,022 5,642 0 40,207 0
Other costs* 1,380 495 1,502 1,912 441 1,408 480 1,432 3,158 270
Total cost of assessment 3,829 3,352 2,754 10,074 441 4,430 5,873 1,737 43,365 270
n = 9 n = 75
Treatment
Drugs 24,558 5,847 23,681 31,575 11,841 22,997 6,065 23,681 31,575 11,841
Hospitalization 12,095 18,902 5,024 58,682 0 6,737 13,427 0 65,041 0
Other costs† 3,856 860 4,187 4,711 2,362 2,463 977 2,265 5,581 952
Total cost of treatment 40,510 22,074 34,894 94,734 16,350 32,197 15,039 27,430 92,832 13,979
n = 7 n = 65
Follow-up
Hospitalization 9,521 18,234 0 47,615 0 1,555 5,669 0 30,967 0
Other costs* 1,196 853 1,387 2,564 0 852 822 800 4,342 0
Total cost of follow-up 10,717 18,889 1,387 50,179 0 2,407 6,018 800 32,590 0
Stage
Limited (n = 20) Advanced (n = 64)
Assessment
Hospitalization 1,804 3,494 0 11,150 0 3,313 5,828 1,844 40,207 0
Other costs* 1,354 457 1,302 2,608 603 1,421 488 1,466 3,158 270
Total cost of assessment 3,158 3,721 1,368 12,437 603 4,734 6,070 2,714 43,365 270
n = 20 n = 64
Treatment
Drugs 18,156 5,924 21,708 23,681 11,841 24,730 5,179 23,681 31,575 11,841
Hospitalization 4,749 13,788 0 50,561 0 8,112 14,168 1,075 65,041 0
Other costs† 2,609 987 2,688 5,056 1,169 2,613 1,082 2,275 5,581 952
Total cost of treatment 25,513 15,217 25,067 67,294 14,432 35,454 15,576 33,315 94,734 13,979
n = 20 n = 52
Follow-up
Hospitalization 1,304 5,830 0 26,070 0 2,725 8,606 0 47,615 0
Other costs* 747 748 628 2,380 0 938 854 890 4,342 0
Total cost of follow-up 2,050 6,130 628 27,921 0 3,663 9,014 890 50,179 0
*“Other costs” indicates the costs occurring during assessment or follow-up except for hospitalization costs.
†“Other costs” indicates the costs occurring during treatment except for drug and hospitalization costs.
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difference between the patients with missing data and
those with complete data. It does raise the issue,
however, of the importance of complete recording of
cost information.
Even though cancer care in Alberta is integrated via
a provincial organization; multiple organizations,
departments, and units are still involved with treatment
of this particularly complex cancer. There is at present
no common costing database; thus, this costing exercise
was quite complex and lengthy. Because multiple
sources of datawere employed, there is a possibility that
some sourcesweremore detailed than others. Also, data
fromparticular sourceswere not necessarily collected in
the same exact time frames, and the matching of the
R-CHOP and CHOP samples was not ideal in a statis-
tical sense. A recommendation to the organizations
involved in cancer care is to coordinate data collection
and to integrate databases so that more precise and
accurate micro-costing can be facilitated.
To the extent that cancer care is performed within
an integrated setting, we maintain that our methods
and results are generalizable to other organizations in
Canada and similar publicly funded systems. Never-
theless, the issue of practice variation (in terms of tests,
imaging, and treatments) across oncologists is impor-
tant. Even within an organization such as the TBCC, in
which “tumor groups” are a mechanism for ensuring
consistent, evidence-based care, it was evident upon
patient chart examination that there is practice varia-
tion across oncologists. We would expect that this
would be even more evident across organizations. This
speaks to the desirability of ensuring that evidence-
based guidelines are devised and followed to the degree
possible to control costs and maximize positive patient
outcomes.
The major components of the total costs were trans-
plantation, drugs, and hospitalization. Stage was a
more inﬂuential factor than age on the total costs. If, for
example, an organization such as the TBCC that oper-
ates under a ﬁxed annual budget is seeking to reallocate
or reduce spending, then any alternative strategies that
reduce costs of transplantation, drugs, or hospitaliza-
tion would likely be preferred. If cost-effectiveness is a
desirable decision criterion, then economic evaluations
that employ information such as ours will potentially
result in more accurate and precise estimates of cost-
effectiveness of R-CHOP or CHOP treatments as rel-
evant to a Canadian context (such economic analyses
will ideally employ careful evaluation of quality-of-life
as a measure of effectiveness). Similar microcosting
Table 8 Patient variables during R-CHOP ﬁrst-line treatment: age and stage group comparisons
Mean SD Med. Max. Min. Mean SD Med. Max. Min.
Age
60 (n = 10) >60 (n = 74)
Assessment
Duration phase (days) 17.0 16.6 13.0 50.0 0.0 25.2 24.2 19.0 0.0 131.0
Hospitalization frequency (%) 50.0 — — — — 47.3 — — — —
Hospitalization length (days) 3.2 3.9 1.5 10 0 3.3 6.1 0 40 0
n = 9 n = 75
Treatment
Duration of phase (days) 151.7 31.1 147.0 189.0 84.0 139.7 34.4 147.0 189.0 63.0
R-CHOP cycles 6.2 1.4 6.0 8.0 3.0 5.8 1.5 6.0 8.0 3.0
Hospitalization frequency (%) 66.7 — — — — 40.0 — — — —
Hospitalization length (days) 8.8 13.3 3.0 42.0 0.0 6.4 14.9 0.0 96.0 0.0
n = 7 n = 65
Follow-up
Duration phase (days) 301.9 52.6 291.0 365.0 227.0 285.1 127.3 365.0 365.0 4.0
Hospitalization frequency (%) 28.6 — — — — 10.8 — — — —
Hospitalization length (days) 8.3 17.9 0.0 48.0 0.0 1.6 6.4 0.0 35.0 0.0
Stage
Limited (n = 20) Advanced (n = 64)
Assessment
Duration phase (days) 36.1 29.2 31.5 131.0 1.0 20.7 20.4 14.5 99.0 0.0
Hospitalization frequency (%) 25.0 — — — — 54.7 — — — —
Hospitalization length (days) 2.7 5.2 0.0 18.0 0.0 3.5 6.0 1.5 40.0 0.0
n = 20 n = 64
Treatment
Duration of phase (days) 117.6 31.5 136.5 147.0 84.0 148.3 31.6 147.0 189.0 63.0
R-CHOP cycles 4.6 1.5 6.0 8.0 3.0 6.3 1.3 6.0 8.0 3.0
Hospitalization frequency (%) 20.0 — — — — 50.0 — — — —
Hospitalization length (days) 3.4 9.6 0.0 32.0 0.0 7.7 15.8 0.0 96.0 0.0
n = 20 n = 52
Follow-up
Duration phase (days) 302.6 103.8 365.0 365.0 36.0 280.6 128.6 365.0 365.0 4.0
Hospitalization frequency (%) 50.0 — — — — 15.4 — — — —
Hospitalization length (days) 1.7 7.4 0.0 33.0 0.0 2.5 8.6 0.0 48.0 0.0
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methods using local data that quantify “door-to-door”
costs for patients could be employed for other forms of
cancer therapy, and indeed are generalizable to other
forms of medical care.
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